Browse News
Filter News
Found 657 articles
-
The Pancreatic Cancer Action Network Names Anna Berkenblit, MMSc, MMSc as First-ever Chief Scientific and Medical Officer
4/2/2024
The Pancreatic Cancer Action Network, the leading nonprofit in the fight against pancreatic cancer, announces Anna Berkenblit, MD, MMSc, a clinical oncologist and drug developer, as its first-ever chief scientific and medical officer.
-
Kyowa Kirin Announces Acceptance of Abstract for Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting 2024
4/2/2024
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.
-
AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
3/25/2024
AVEO Oncology (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer.
-
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
3/8/2024
XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its fourth quarter and full year 2023 financial results and highlighted portfolio activities expected to drive long-term shareholder value.
-
Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema
2/6/2024
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel group study of tivozanib eye drops (KHK4951).
-
Actinium Announces Acceptance of Five Abstracts for Presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
1/2/2024
Actinium Pharmaceuticals, Inc. today announced that five abstracts have been accepted for presentation at the 2024 Tandem Meetings | Transplantation & Cellular Therapy (TCT) Meetings of ASTCT® (American Society for Transplantation and Cellular Therapy and CIBMTR® (Center for International Blood and Marrow Transplant Research) being held February 21 – 24, 2024 in San Antonio, Texas.
-
Actinium Announces Iomab-B Produces High Response Rates and Significant Improvement in Overall Survival in Relapsed Refractory AML Patients with Active Disease Overcoming TP53 Mutation
12/11/2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in an oral presentation at the 65th Annual American Society of Hematology Meeting & Exposition (ASH).
-
Actinium's Four Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with Relapsed or Refractory Acute Myeloid Leukemia
12/11/2023
Actinium Pharmaceuticals, Inc. today highlighted four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) detailing results from the Phase 3 SIERRA trial of Iomab-B and Phase 1 trial of Actimab-A in combination with Venetoclax in patients with relapsed or refractory acute myeloid leukemia (r/r AML).
-
Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
12/8/2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting & Exposition (ASH) being held in San Diego on December 9-12, 2023.
-
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
12/7/2023
IN8bio, Inc. today announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors.
-
AVEO Oncology, an LG Chem company, Earns Spot on Boston Globe's 2023 Top Places to Work List for Second Consecutive Year
11/30/2023
For the second year in a row, AVEO Oncology, an LG Chem company, has earned a spot on the Boston Globe's annual 'Top Places to Work in Massachusetts' list.
-
Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations
11/6/2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced data was presented at Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting on Saturday, November 4, 2023.
-
Actinium Appoints Lynn Bodarky as Chief Business Officer
11/3/2023
Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, announced that Lynn Bodarky has been named Chief Business Officer to lead the Company's business development, licensing, and collaboration activities.
-
Actinium Announces Oral Presentation at ASH Annual Meeting Highlighting Iomab-B Treatment Significantly Increased Median OS in Relapsed or Refractory AML Patients with Highly Unfavorable TP53 Gene Mutation in the Phase 3 SIERRA Trial
11/2/2023
Actinium Pharmaceuticals, Inc. announced that three abstracts detailing results from the completed Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia have been accepted for presentation at the 65th Annual American Society of Hematology Annual Meeting & Exposition being held in San Diego on December 9-12, 2023.
-
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
11/2/2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will be attending Bio-Europe, the largest biopharmaceutical industry partnering event in Europe, taking place November 6 – 8, 2023 in Munich, Germany.
-
Mestag Therapeutics announces the appointment of expert advisors Dr. Cassandra Choe-Juliak, Dr. Greg Elson and Samantha Vieira MBA
10/12/2023
Mestag Therapeutics announced the appointment of expert advisors Dr. Cassandra Choe-Juliak MD, formerly Chief Medical Officer at Flame Biosciences; Dr. Greg Elson, an expert in end-to-end development of novel antibody-based products with more than 30 years of industry experience; and Samantha Vieira MBA PMP, formerly Chief Operating Officer at Anjarium Biosciences.
-
Actinium Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
10/4/2023
Actinium Pharmaceuticals, Inc. announced the National Institutes of Health (NIH) awarded Actinium a Small Business Technology Transfer grant extension to support its clinical collaboration with Memorial Sloan Kettering Cancer Center (MSK) to study Iomab-ACT.
-
Actinium Pharma Highlights Abstract Accepted for Poster Presentation at the SITC 38th Annual Meeting
9/27/2023
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today details an abstract accepted for poster presentation at the upcoming Society of Immunotherapy of Cancer (SITC) 38th Annual Meeting, which will be held in San Diego, November 3-5, 2023.
-
Actinium Pharma Presents Survival Data from Extended Follow-Up from Actimab-A + CLAG-M Trial and Preclinical Data Supporting Program Expansion with FLT3 Inhibitor Combinations at SOHO
9/7/2023
Actinium Pharmaceuticals, Inc. today highlighted updated survival data from its Phase 1b trial evaluating Actimab-A in combination with the salvage chemotherapy CLAG-M in patients with high-risk relapsed or refractory acute myeloid leukemia (r/r AML) and new preclinical data with Actimab-A in combination with FLT3 inhibitors at the Society of Hematologic Oncology (SOHO) 2023 Annual Meeting.
-
CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations
9/5/2023
CG Oncology, Inc. announced the appointment of three new members to its executive leadership team: Ambaw Bellete as President and Chief Operating Officer, Swapnil Bhargava, Ph.D. as Chief Technical Officer, and Vijay Kasturi, M.D. as Chief Medical Officer.